NCT01715168View on ClinicalTrials.gov

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions
Ovarian CancerMalignant Female Reproductive System NeoplasmCancerOvarian TumorOvarian Epithelial Cancer Recurrent
Interventions
DRUG

DOXIL/CAELYX

DRUG

ATI-0918

Trial Locations (2)

98902

Yakima Valley Memorial Hospital - North Star Lodge, Yakima

H2L4M1

Centre Hospitalier de L'Universite de Montreal (CHUM), Montreal

Sponsors
All Listed Sponsors
lead

Azaya Therapeutics, Inc.

INDUSTRY

NCT01715168 - A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer | Biotech Hunter | Biotech Hunter